Open AccessA Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus–Associated Chronic Inflammation
Author(s) -
Bernard Macatangay,
Edwin K. Jackson,
Kaleab Z. Abebe,
Diane Comer,
Joshua C. Cyktor,
Cynthia Klamar-Blain,
Luann Borowski,
Delbert G. Gillespie,
John W. Mellors,
Charles R. Rinaldo,
Sharon A. Riddler
Publication year - 2019
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiz344
Subject(s) - dipyridamole , medicine , adenosine , placebo , pharmacology , immunology , inflammation , endocrinology , pathology , alternative medicine
Adenosine is a potent immunoregulatory nucleoside produced during inflammatory states to limit tissue damage. We hypothesized that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosine concentration and dampen chronic inflammation associated with human immunodeficiency virus (HIV) type 1.